Skip to content

    Recently Viewed

      Listening...

      Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes

      Share Article
      share to

      New Brunswick, NJ (September 26, 2012) – Janssen Research & Development, LLC and Johnson & Johnson will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2, at approximately 12:00 p.m., Eastern Time, to coincide with the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany.

      First results from the ongoing phase 3 CANVAS trial evaluating canagliflozin in patients with type 2 diabetes at elevated risk for cardiovascular disease will be shown at EASD. Additionally, data from DIA3010, which evaluated canagliflozin as add-on therapy in patients aged 55 to 80, on antihyperglycemic therapy without adequate glycemic control, will be presented.

      A pre-recorded webcast with Kirk Ways, M.D., Ph.D, Vice President and compound development team leader for canagliflozin from Janssen Research & Development, will provide an update on the CANVAS sub-study and DIA3010 results.

      The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

      ###

      Press Contacts:
      Al Wasilewski
      (732) 524-1130

      Bill Price
      (732) 524-6623

      Investor Contacts:
      Stan Panasewicz
      (732) 524-2524

      Louise Mehrotra
      (732) 524-6491

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.